Also known as: BI 456906 · BI-456906
Survodutide (BI 456906) is a GLP-1/glucagon dual receptor agonist co-developed by Boehringer Ingelheim and Zealand Pharma. It achieved 14.9% weight loss over 46 weeks (Phase 2) and showed breakthrough Phase 2 results for NASH/MASLD resolution — one of the most promising agents for liver disease in its class.
Survodutide was developed using Zealand Pharma's glucagon-based peptide engineering and is co-developed with Boehringer Ingelheim. It has a distinct molecular architecture with intentionally higher glucagon receptor potency relative to GLP-1 activity — a differentiated profile suited for liver disease indications.
Phase 2 NASH results were particularly notable: survodutide achieved NASH resolution without worsening of fibrosis in 83% of responders — a landmark result in an indication that has historically resisted pharmacological resolution.
Survodutide activates both GLP-1R and GCGR with an intentionally higher GCGR:GLP-1R activity ratio compared to other dual agonists. This amplifies hepatic fat oxidation effects.
Glucagon receptor activation upregulates PPAR-α, promoting mitochondrial beta-oxidation of fatty acids and reducing hepatic triglyceride accumulation.
Phase 2 data showed concomitant fibrosis improvement, likely through reduced hepatic stellate cell activation secondary to reduced lipotoxicity and inflammation.
Survodutide is distinguished from other dual GLP-1/glucagon agonists by its intentionally higher glucagon receptor potency ratio — a deliberate design choice to maximize hepatic fat metabolism for the NASH/MASLD indication. This higher glucagon activity may produce more nausea during titration than equivalent GLP-1/glucagon agents. Phase 2 NASH data showing 83% resolution in responders was among the strongest results reported for any NASH agent. Not yet approved as of 2024.
NASH treatment requires sustained histological improvement, which necessitates long-term continuous therapy. Phase 3 FRONTIER trials are run at 48–72 weeks to demonstrate sustained fibrosis improvement. The obesity indication follows the standard chronic-use GLP-1 model. No cycling protocols have been evaluated for this compound.
Higher glucagon receptor potency means stronger thermogenic and potentially pro-glycemic effects — monitor blood glucose carefully in diabetic patients during titration. GI adverse effects may be more pronounced than with pure GLP-1 agonists during the escalation phase.
Phase 2 obesity (46 weeks): 14.9% weight loss at 4.8 mg vs. 2.8% placebo. Phase 2 NASH/MASLD (48 weeks): 83% of high-dose responders achieved NASH resolution without fibrosis worsening (vs. 18% placebo); fibrosis improvement in 54% vs. 18% placebo.
Ask anything about Survodutide — mechanisms, dosing protocols, interactions, or research comparisons.
Semaglutide is an FDA-approved GLP-1 receptor agonist used for type 2 diabetes (Ozempic) and chronic weight management (…
Tirzepatide (Mounjaro/Zepbound) is the first FDA-approved dual GIP/GLP-1 receptor agonist, developed by Eli Lilly. It pr…
AOD-9604 is a modified fragment of human growth hormone (hGH residues 177–191) with an added N-terminal tyrosine residue…
Cagrilintide (AM833) is a long-acting amylin analogue developed by Novo Nordisk. It mimics the satiety and gastric-empty…